1.
|
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: U2963n, NCT00097565
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-CD20-405, NCT00394836
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: U4391g, NCT00719472
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LYMNHL0014, 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: WU-6071, 6071, FHCRC-6071, NCI-6957, 6957, UWCC-UW-6071, UWCC-06-0644-H/A, NCT00288067
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CY 2121, NCT00343564
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB# 29960007, NCT00634179
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: MOZ00207, NCT00694590
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0403, NCT00724984
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0484, NCT00787527
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 to 75
Sponsor: NCI
Protocol IDs: UNMC-16407, 164-07, NCT00816413
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0178, NCT00019370
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0284, NCI-5744, NCT00047164, 5744
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: BIDMC-2004P-000044, NCT00110149
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FAV-ID-70, FAV-ID-LYM-31, NCT00258336
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: JHOC-J0260, J0260, JHOC-03022409, NCT00278161
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1048-2001, NCT00208975
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: LYMNHL0020, 4328-07, 95140, LYMNHL0020, NCT00185731, NCT00185731
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PXD101-CLN-6, NCT00274651
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0004, NCT00290433
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: NCI
Protocol IDs: UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
|
